Here is all you need to know about Aerpio Pharmaceuticals Inc (ARPO) stock
Aerpio Pharmaceuticals Inc. (ARPO) shares surged 3.55% to $1.72 in the premarket on Thursday, May 27, 2021. ARPO ‘s stock price remained unchanged in the morning session Wednesday. ARPO shares have surged 116.11% over the last 12 months, and they have moved down 23.87% in the past week. Over the past three months, the stock […]
Aerpio Pharmaceuticals Inc. (ARPO) stock falls during after-hour. Here’s to know why?
Aerpio Pharmaceuticals Inc. (NASDAQ: ARPO) stock surged by 12.61% at last close whereas the ARPO stock price declines during after-hour by 5.41%. Aerpio Pharmaceuticals is a biopharmaceutical corporation that focuses on discovering compounds that activate Tie2 for situations where ARPO claims Tie2 activation may be therapeutic. Significant Developments Aadi Bioscience which is a privately owned […]
Aerpio Pharmaceuticals Inc. (ARPO) stock surged in the current trading session; here’s why
At last check, in the current trading session, Aerpio Pharmaceuticals Inc. (ARPO) stock had surged by 48.70% to $1.72. ARPO stock previously closed the session at $1.16. The stock volume traded 96.55 million shares. In the past year, up-to-date ARPO shares surged by 59.45% and in the past week, they moved up by 10.48%. In […]
Pre-Market Top Losers Today
Pre-market data show Apartment Investment and Management Company (NYSE:AIV) is -6.55% lower at $4.71 after reporting that it has completed separation of Apartment Income REIT Corp. It recently closed at $5.04, fluctuating in a day’s range from $4.88 to $6.48. Scotiabank has a Sector perform rating on AIV’s shares and set a $41 price target. […]
Is that why Aerpio Pharmaceuticals (Nasdaq: ARPO) stock plunged in the AH session?
Aerpio Pharmaceuticals, (Nasdaq: ARPO), the stock dipped -40.89% to $1.33 in the After-market session, as Razuprotafib met its primary efficacy endpoint at 28 days in Aerpio’s double-blind Phase 2 trial in patients with elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. Compared to the monotherapy group, razuprotafib did not show any statistically significant […]
